What is your role in the REDDIE team at your institution?

As a postdoc in the REDDIE team, my role is multifaceted, aimed overall at contributing to the achievement of the objectives outlined in Work Package 4 (WP4). My responsibilities include drafting analysis plans for the emulation studies we aim to conduct within WP4, managing data by combining relevant datasets from the Danish registries, and conducting detailed analyses in collaboration with the statistical team. Additionally, I contribute to the authorship of scientific papers, encapsulating our findings and methodologies for the academic community.

What are you currently working on within the scope of REDDIE and what are your main goals and objectives in the project?

Currently, I am focused on finalizing the analysis plan for our study comparing GLP-1 and DPP-4 inhibitors. We aim to utilize the Longitudinal Targeted Maximum Likelihood Estimation (LTMLE) method to derive preliminary results very soon. Furthermore, I am supporting data management efforts across other projects in line with the objectives of WP4.

What are some of the most interesting findings or insights that you have gained or are expecting to gain from your research in REDDIE?

One of the most enriching aspects of working on WP4 within REDDIE has been the opportunity for international collaboration. This bi-country initiative has facilitated a cross-pollination of ideas and approaches which is something I find both fascinating and invaluable.

What makes working on the REDDIE project special for you personally?

The Danish WP4 group is an interdisciplinary team and with backgrounds in mathematics, biostatistics, endocrinology, cardiology, and epidemiology, we are able to complement each other's expertise, fostering a learning and working environment that I very much enjoy.

How do you see using real-world data to impact diabetes care in the future?

While randomized trials remain the gold standard for clinical research, I am optimistic about the growing role of Real-World Data (RWD) in uncovering treatment heterogeneity among patients. The advancement of refined analytical methods allows us to leverage RWD more effectively, providing insights that could potentially lead to personalized and improved diabetes care.

Could you share with us what are you currently reading?

I'm currently reading the book Invisible Women: Exposing Data Bias in a World Designed for Men. It's an important book, shedding light on how societal norms and structures often overlook women, treating men as the standard. The book elegantly points out the pervasive bias at all societal levels, from public policy decisions like snow-clearing to emergency management during natural disasters – I highly recommend.

What is your role in the REDDIE team?

I am an alliance manager and working with research and innovation strategies and initiatives at Novo Nordisk, e.g. as a representative in various industry groups at EFPIA and MedTech Europe.

What are you currently working on within the scope of REDDIE and what are your main goals and objectives in the project?

As part of the coordination team and managing board, I participate in the overall project leadership with a special focus on the industry and pharma perspective. The main goal is to bring the relevant stakeholders together to jointly discuss and test how to apply real-world evidence to the various decision-making processes in healthcare provision. This is a common goal believed to improve healthcare for the benefit of patients and society.

What are some of the most interesting findings or insights that you have gained or are expecting to gain from your research in REDDIE?

It is interesting to see how many different approaches to bringing real-world evidence to the table are being considered and tested in different environments, whether locally in some countries, driven by EMA or the EC, or by academia and industry groups. My hope is that we can join forces and work together on aligned solutions, which supplement each other.

What makes working on the REDDIE project special for you personally?

The REDDIE consortium brings together a fantastic team of experts and leaders to tackle one of the key topics in healthcare. It is great to work with such a dedicated and experienced group of people bringing in the broad and diverse perspectives making this a true joint effort.

How do you see using real-world data to impact diabetes care in the future?

Real-world data will be an integrated part of the development and treatment processes in the future, providing more targeted and efficient treatments to patients.

What is your favourite thing when not doing research?

One of my favourite things to do when not doing research is playing music. I play the clarinet in two different orchestras spanning from classical music to popular music of the last 100 years. This is great fun, both challenging and rewarding, when we see people enjoying our concerts.

What is your role in the REDDIE team at your institution?

I am the project coordinator.

What are you currently working on within the scope of REDDIE, and what are your main goals and objectives in the project?

Currently, I am working on the publication guidelines. My main goal is to prove that real-world data are a relevant adjunct to data obtained from randomized controlled trials and that we can develop standards on data type and quality so that real-world data sets can be evaluated for their validity and usefulness to be used as relevant data sources.

What are some of the most interesting findings or insights that you have gained or are expecting to gain from your research in REDDIE?

Currently, we are still in the development phase. Findings will be available in the coming years. However, I have already gained insight into the regulatory aspects of the use of RWD (real-world data).

What makes working on the REDDIE project special for you personally?

It is my great honour and pleasure to work with world leaders in the field of real-world evidence and diabetes care. I am so happy to work with a consortium that is smart and with whom you can also spend a good time during social events.

How do you see using real-world data to impact diabetes care in the future?

RWD will help us to faster adopt findings from RCTs (Randomised Controlled Trials) into clinical care and include special populations (e.g. elderly) into the indications as we can model data for special populations that are normally not represented in clinical trials.

What is one thing you cannot live without?

One thing I cannot live without would be good company, delicious food, and tasteful wine – sorry, these are three, but always go together.

What is your role in the REDDIE team?

I am the principal investigator at Ulm University.

What are you currently working on within the scope of REDDIE and what are your main goals and objectives in the project?

Our research group is currently working on a trial-inspired analysis investigating the efficacy of liraglutide versus placebo on metabolic control in people with diabetes. The main objectives are to compare results between studies using real-world data (RWD) and randomised controlled trials (RCT), to present RWD as an important complement to RCT and further to improve the use of RWD in order to advance research related to diabetes.

What are some of the most interesting findings or insights that you have gained or are expecting to gain from your research in REDDIE?

I am expecting that within REDDIE we will present important and interesting differences, similarities and new aspects when comparing RCT and RWD studies.

What makes working on the REDDIE project special for you personally?

For me exchanging expertise with people from different disciplines on an international level is special and helps to advance my own expertise in diabetes research.

How do you see using real-world data to impact diabetes care in the future?

The use of RWD as a complement to RCT will potentially enhance our understanding of diabetes, guide treatment decisions and improve outcomes for people with diabetes.

What is your favourite thing when not doing research?

One of my favourite things to do when not doing research is running. I love being physically active outside in nature.